Answer
Monofer (ferric derisomaltose) requires careful risk–benefit evaluation because pregnancy data are limited, should be confined to the second and third trimesters only when benefits outweigh potential risks to mother and foetus, and requires careful monitoring of the unborn baby during administration because foetal bradycardia may occur.
Sources for this answer
- Monofer 100 mg/ml solution for injection/infusionPharmacosmos UK Limited · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 20Document updated
Sources checked